Such results, thus suggest that a therapeutic strategy aiming at reducing IL-4, IL-10, and IL-13 could also, beyond the direct immune-cell-related role of these cytokines, improve the skin barrier integrity of patients with AD. Here, IL13 is linked to Alzheimer disease.